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Abstract
Background: Prostate-specific membrane antigen (PSMA) is a promising target for diagnostics and therapy of
prostate carcinoma (PCa). Based on the hypothesis that PSMA expression can be modulated by variations in
androgen deprivation therapy (ADT), we investigated the binding of a PSMA-directed radiopharmaceutical in vitro
in order to get an insight of the interactions between altered premedication and PSMA expression before repetitive
PSMA-directed PET/CT for therapy response and targeted therapy implementation.
Methods: The human castration-resistant PCa cell line VCaP (CRPC) was treated with either 1 nmol/L testosterone (T)
over 20 passages yielding the androgen-sensitive cell line (revCRPC) or with 5 μmol/L abiraterone acetate (AA)
generating the abiraterone-tolerant subtype CRPCAA. In these cell lines, T and AA were varied by either supply or
withdrawal of T and AA. PSMA expression of the three cell culture models was detected by Western blot and
immunohistochemical staining. For quantitative measurement of tracer uptake, 0.3 nmol/L 68Ga-labelled PSMA-HBED-
CC peptide (100–300 kBq/ml) was added to different treated parallel cultures (n = 9 each). Time-dependent uptake per
106 cells of each culture was calculated and evaluated. PSMA mRNA expression was investigated by qPCR.
Results: PSMA expression increased dependently on intensified ADT in all three basic cell lines. 68Ga-PSMA-HBED-CC
uptake almost doubled during 3 h in all cell lines (p < 0.01). Compared to the basic cells, pre-incubation with
abiraterone for 48 h resulted in a significant increased uptake in CRPC (p < 0.001). In revCRPC, 48-h AA pre-incubation
resulted in an eightfold higher uptake after 3 h (p < 0.001). Additional withdrawal of external testosterone increased the
uptake up to tenfold (p < 0.01). The increase of PSMA expression upon ADT and AA treatments was confirmed by qPCR
and Western blot data. Furthermore, in CRPCAA, 48-h AA withdrawal increased the uptake up to fivefold (p < 0.01).
Conclusions: The investigated three PCa cell culture subtypes represent a serial preclinical model of androgen
deprivation therapy as a proxy for clinical situations with differing basal PSMA expression. The uptake of PSMA-binding
tracers could be stimulated by therapeutic effective short-term variation in premedication in all stages of ADT response.
These complex interactions have to be considered in the interpretation of diagnostic imaging using PSMA ligands as
well as in the optimal timing of PSMA-based therapies.
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Background
Prostate cancer (PCa) became the most frequent can-
cer amongst men in Europe with an incidence in-
creasing rapidly over the past two decades [1, 2].
Localised PCa can be curatively treated by radical
prostatectomy or various radiotherapies and/or andro-
gen deprivation therapy in some cases [3]. However,
castration-resistant PCa (CRPC) from de novo meta-
static or relapsed disease remains incurable even after
the advent of recently developed highly active agents
such as abiraterone (Zytiga®, an inhibitor of steroido-
genesis) and enzalutamide (Xtandi®, a second-
generation androgen receptor antagonist). Moreover,
very recently, the sequential use of individual potent
agents confronted therapists with still insufficiently
explained the cross-resistance phenomena [4]. Under
such conditions, when de facto highly potent thera-
peutics are compromised by prior use of another po-
tent agent, indicative biologic markers for the
usefulness of a subsequent therapy are required. Re-
cently, prostate-specific membrane antigen (PSMA)
has been introduced as an indicator of androgen re-
ceptor signalling in PCa by PET imaging [5]. In
this study, we introduce PSMA as potential thera-
peutic target after exhaustive androgen deprivation
therapy with abiraterone acetate, an inhibitor of
steroidogenesis.
PSMA with the biologic function of glutamate carboxi-
peptidase II (GCPII) is a membrane-bound zinc metal-
loenzyme and is expressed in various tissues. GCPII
catalyses the reaction of N-acetylaspartylglutamate
(NAAG) with water to result in N-acetylaspartate
(NAA) and glutamate [6]. While the role of this enzyme
in central and periphery nervous system seems to be
well understood, its role in prostate and prostatic cancer
cells as well as in neovascularity of other tumours is still
under discussion. Glutamate as a potent nitrogen source
in biosynthesis, and aspartate plays a central role in the
synthesis of androgens. Other functions of this protein
like its folate hydrolase activity may have an additional
impact for tumour growth [7].
Since the expression of PSMA in the prostate is
nearly 100-fold higher than in other tissues and pros-
tate cancer exhibits a tenfold higher expression than
the healthy prostate, PSMA has become a conspicu-
ous target for nuclear medicine diagnostics and
therapy very recently. Since the 1990s several radio-
pharmaceuticals directed against PSMA were estab-
lished [8–12]. Today several groups use PSMA-based
PET for the diagnostics of PCa with excellent sensitiv-
ity based on a very high contrast [13–17]. Conse-
quently, the preferable imaging quality and clear
visualisation resulted in questions about therapy re-
sponse especially in patients with metastatic PCa
during androgen deprivation therapy (ADT). During
the last decades, choline analogues labelled with 11C
and 18F were the ‘gold-standard’ in nuclear medicine
PCa imaging [18, 19]. Furthermore, they were used
for staging and therapy monitoring. Nevertheless,
2 years ago, Dost et al. reported data about the influ-
ence of ADT on choline PET/CT and commented on
the lack of in vitro data on that issue [18].
To avoid repetition of that problem we focused on
provision of basic investigations prior to ubiquitary
use of PSMA-directed tracers. There are basic infor-
mation of the influence ADT on PSMA expression in
vivo [20]. For castration-resistant cancer cells, it has
already been described that ADT increases PSMA ex-
pression [21]. Recently, hormone withdrawal com-
bined with additional suppression of endogenous
androgen synthesis and/or blockade of androgen re-
ceptors is one major strategy in PCa therapy [3, 22].
However, only a small portion of patients scheduled
for PSMA-PET/CT suffered from castration-resistant
PCa. These patients are usually investigated based on
increasing PSA serum level prior or after therapy al-
terations. Whereas the impact of increasing standard-
ized uptake value (SUV) and/or detection of
additional lesions after therapy variation in these pa-
tients is unknown in that particular situation.
Various patients will receive their primary scan prior
to prostatectomy in ADT-naïve situation. Follow-up
with PSMA PET/CT will be performed based on very
low and slightly increasing PSA serum levels, perhaps
for planning of pelvic lymph node dissection. If ADT
should be performed prior to PSMA PET/CT is as
yet unclear.
Some patients will be scheduled for PSMA-based
radionuclide therapy subsequent to ADT. It remains a
central question if these patients will profit from ADT
intermission.
Therefore, in vitro data for the whole spectra of po-
tential clinical situations from hormone-naïve prostate
cancer to androgen-deprivation-tolerant PCa should
be available. For this aim, our group established a cell
culture system, which reflects several aspects in PCa
therapy re-establishing an androgen-sensitive subtype
(revCRPC), the castration-resistant CRPC origin and
the abiraterone-tolerant subtype. In this system, we
focused on the time dependency of the uptake, the
changes of PSMA expression as well as uptake of a
PSMA-binding radiopharmaceutical after supply and
withdrawal of testosterone and abiraterone acetate to
avoid misinterpretations in vivo. Additionally, the
clinical long-term objective is stimulation of PSMA
expression by premedication sensitising the detection
of primary and recurrent PCa and its metastases for
diagnostics as well as for PSMA-directed therapy.
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Methods
Radiolabeling of PSMA-HBED-CC
Elution of a 68Ge/68Ga-Generator (iThemba Labs, Cape
Town, South Africa) was performed with 6 mL 1 M
HCl, and the eluate was diluted with 6 mL H2O.
68Ga
was retained on a cation exchange cartridge (Reagent
and Hardware Kit SC-01, ABX, Radeberg, Germany) in a
GRP Module (Scintomics, Lindach, Germany). M = 1200
(600–2000) MBq 68Ga was eluted from the resin with
1.5 mL 5 M NaCl. Radiolabeling of 5 μg (5.3 nmol)
PSMA-HBED-CC in 3 mL 1.5 M HEPES (Kit compo-
nents, ABX, Radeberg, Germany) was performed during
10 min at 95 °C in a reaction vessel for single use from
the kit. Purification of the product was performed as
already described by Eder et al. [23]. Radiochemical pur-
ity was determined by TLC and HPLC (Additional file 1).
In contrast to the described methods, we used an Agilent
1200 Series HPLC equipped with a 250 × 4.6 mm
Lichrosorb RP C18, 5 μm column (NORDANTEC,
Bremerhaven, Germany) with the described mobile phases
(A aqueous 0.1 % trifluoroacetic acid (TFA), B acetonitrile
with 0.1 % TFA) and a linear gradient starting with 100 %
A to 90 % B after 12 min and followed by 3 min equilibra-
tion with 100 % A, flow rate 1 mL/min.
Cell culture subtypes
All cells were cultured in 25 cm2 culture flasks in 7-ml
DMEM medium supplemented with 1 % L-glutamine
(Lonza, Basel, Switzerland), 10 % FCS (PAA, GE Health-
care Bio-Sciences, Uppsala, Sweden) and 2 % sodium
pyruvate (Gibco, Karlsruhe, Germany). Cell cultures
were used below 40 passages after subtype development.
Castration-resistant prostate cancer (CRPC): the hu-
man cell line VCaP derived from a hormone-refractory
bone metastasis was obtained from the American Type
Culture Collection (ATCC; CRL-2876, Wesel, Germany).
This cell line proliferates without androgen supply.
Revert castration-resistant prostate cancer (revCRPC):
this cell line represents the pre-CRPC phenotype and
was subcultured with 1 nmol/L testosterone (Sigma, St.
Louis, MO, USA) over at least 20 passages resulting in a
steady androgen-sensitive subtype for experiments
within the subsequent 10 passages [24].
Abiraterone acetate tolerant castration-resistant pros-
tate cancer (CRPCAA): CRPCAA was obtained by sub-
culturing CRPC with 5 μmol/L abiraterone acetate over
at least 20 passages.
Western blot analysis of the cell culture subtypes
Total protein lysates were prepared using RIPA buffer
with protease inhibitors (Roche, Mannheim, Germany)
and were quantified using the Bio-Rad DC Protein Assay
(Bio-Rad, Hercules, California, USA). The samples were
prepared for gel electrophoresis by mixing each with 4×
Laemmli buffer (Bio-Rad). Each well of the gel was
loaded with 15 μg protein. The gel was run for approxi-
mately 30 min at 250 V in the Mini-PROTEAN® Tetra
System with the POWER PAC 300 (both Bio-Rad). The
blotting step was carried out with the Bio-Rad Trans-
Blot®Turbo™ RTA Transfer kit onto a nitrocellulose
membrane. The membrane was blocked with 5 % milk
powder in TBS buffer with 0.5 % Tween for 1 h at room
temperature. For protein analysis, the primary antibody
against PSMA (Dako M3620, monoclonal mouse, diluted
1/500, overnight at 4 °C) was used. The housekeeping
gene α-tubulin (monoclonal mouse, diluted 1/5000) was
labelled at room temperature for 1 h. The primary anti-
bodies were detected with HRP-labelled anti-mouse sec-
ondary antibodies (Dako, dilution 1/1000). The signal
development was made visible by applying a chemilu-
minescent substrate (ECL system by Amersham
Bioscience, Freiburg, Germany).
Immunohistochemistry—cell blocks
Immunohistochemical analyses were performed as de-
scribed previously [25]. Adherent tumour cell lines were
trypsinised from culture flasks and washed with PBS.
Cells were spun down at 300g for 5 min. The pellet was
fixated with 1 ml 4.5 % formalin for 1 min through re-
suspension. After another centrifugation, the formalin
was removed, and the cell pellet was resuspended in
200 μl liquid 3 % agarose gel. The gel pellets were dried
overnight at room temperature, then the hardened gel
cones were removed from the cups and cut lengthwise.
These gels cones were put into tissue capsules for the
pre-treatment and following paraffin embedding. Paraf-
fin blocks were cut at 3 μm for immunohistochemistry.
Sections were stained using a Dako autostainer with the
Dako EnVision™ FLEX+ detection system (Dako,
Glostrup, Denmark). The system detects primary mouse
and rabbit antibodies, and the reaction was visualised by
EnVision™ FLEX DAB+ Chromogen. Using EnVision™
FLEX+ Mouse (LINKER) or EnVision™ FLEX+ Rabbit
(LINKER) (Code K8019), signal amplification of primary
antibodies can be achieved. Deparaffinisation, rehydra-
tion and heat-induced epitope-retrieval (HIER) was car-
ried out in one step with the 3-in-1 procedure buffer
(Dako, Glostrup, Denmark, Target Retrieval Solution),
pH 9 high ((10×) (3-in-1) Code S2375)) at 97 °C using a
PT Link, Pre-Treatment Module 6 (Dako). Tissue sam-
ples were analysed by light microscopy after 8 min coun-
terstaining with Meyer’s haematoxylin (Dako). As
primary antibodies, we used anti-PSMA (Dako M3620,
monoclonal mouse antibody, diluted 1:50, 30 min).
Uptake measurements and cell count
All uptake experiments were carried out in three separ-
ate series resulting in n = 9 culture flasks for each cell
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line, variation in medication and measurement time. To
assess the capacity of cells for the labelled compounds in
one series, 0.3 nmol/L 68Ga-labelled peptide (100-
300 kBq/ml) was simultaneously applied to three parallel
cells cultures for each interval (1–3 h) and each cell line.
Since activity yield from generator, yield of synthesis as
well as delay between synthesis and cell culture experi-
ments differed between the experimental series, peptide
amount kept constant between the separate series. Be-
fore measuring the tracer uptake, culture medium was
discarded, and the cells were washed twice with phos-
phate buffered saline (PBS) buffer pH 7.4. The cells were
dissociated by accutase/EDTA (PAA, GE Healthcare
Bio-Sciences, Uppsala, Sweden) and centrifuged. Activity
of cell pellet and collected supernatants was measured.
Data were half-life-corrected, and percentage uptake of
applied activity was calculated. Since differences in treat-
ment resulted in altered proliferation, the calculated up-
take was correlated to the determined cell count in each
particular culture flask and normalised to 106 cells as
already described [26, 27].
Variations of abiraterone acetate and testosterone
treatment
CRPC and revCRPC cells were incubated over 48 h with
5 μmol/L Abiraterone acetate (Janssen-Cilag, Neuss
Germany) prior to activity supply. In parallel revCRPC
cultures abiraterone acetate (AA)-induced androgen
deprivation was aggravated by testosterone withdrawal.
In CRPCAA cells, AA was eliminated from culture
medium and 1 nmol/L testosterone was supplied.
Analysis of mRNA expression
mRNA expression of 106 cells per sample were analysed
by qRT-PCR. Total cellular RNA from cultured cells was
extracted with the Quick-RNA™MiniPrep (Zymo Re-
search, Freiburg, Germany). Total RNA integrity and
quantity were assessed on an Experion™ Automated
Electrophoresis System with analysis kits consisting of
microfluidic chips and reagents (Bio-Rad, Munich,
Germany). Reverse transcription of 500 ng total cellular
(tc) RNA was performed with random hexamer primers
and an Omniscript RT Kit (QIAGEN, Hilden, Germany).
Expression analyses were processed on a CFX96™ real-
time detection system (Bio-Rad, Munich, Germany) with
SsoAdvanced Universal SYBR Green supermix. The
20 μl reaction mix from the kit was supplemented with
2 μl cDNA, 0.6 μM gene-specific primers (IBA, Goettin-
gen, Germany). Primers were designed by Primer 3
[http://primer3.ut.ee] and assessed for PCR efficiency.
Time courses of gene expression (Fig. 3) were calcu-
lated as percent expression using the analysis of relative
gene expression by real-time quantitative PCR and the
2(-ΔΔC(T)) method [28]. The housekeeping gene for
calculation of relative expression was acidic ribosomal
protein (ARP) and for proof of principle of this calcula-
tion another housekeeping gene ribosomal protein L13a
(RPL) was used.
Internalisation
To elucidate if the three different subtypes or modifica-
tion of medication resulted in different internalisation
rates, a protocol for the detection of endocytosis in
adherent cell lines was modified [29]. CRPC, CRPCAA,
rev-CRPC as well as rev-CRPC under ADT (with abira-
terone acetate and testosterone withdrawal) were investi-
gated. Therefore, three cultures flasks (25 cm2) for each
subtype and modification were seeded with 3 × 105 cells
and allowed to attach overnight in their specific me-
diums as described above. All cultures were grown for
an additional 48 h whereby ADT was performed for
three flasks as already described above. Cultures were in-
cubated with 0.3 nmol/L 68Ga-HBED-CC for 5 h. In
contrast to the mentioned protocol, adherent cells were
harvested with trypsin/EDTA (PAA). Total activity was
determined in culture medium, in the fraction of
stripped radiolabel from cell surface proteins and the
harvested cells. Thereafter, cells were spun down and
total cell count was determined. Results were calculated
as percentage of fraction activity normalised to 106 cells
of applied activity after half-life correction.
Statistical analysis
Statistical analyses (Statistical Analysis Software: SPSS
Statistics 22.0 for Windows) were performed using non-
parametric tests (Wilcoxon, Mann-Whitney). Means (m)
and standard deviations (SD) were calculated. Differ-
ences were considered significant when p < 0.05.
Results
The radiolabelling of PSMA-HBED-CC with 68Ga was
performed in high radiochemical purity (m = 98.7 %,
range 95.7–99.9 %) and yield (m = 379 MBq, range
290–468 MBq) with specific activities of m =
71.5 GBq/mmol (range 54.7–88.3 GBq/mmol).
PSMA protein expression was visualised by Western
blot in all three different cell lines at 100 kDa (Fig. 1a).
The lowest PSMA protein expression was observed in the
androgen-sensitive cells by chemiluminescent detection.
The highest expression was detected in the abiraterone-
tolerant variant (Fig. 1b). The housekeeping gene α-
tubulin tended slightly to decrease in the same order.
Different PSMA protein expressions could be
confirmed by immunohistochemical staining of paraffin
embedded cells (Fig. 2). In revCRPC, cells were only par-
tially stained by PSMA antibodies (Fig. 2a/b). With in-
creasing castration, resistance staining increased within
cell lines (CRPC (Fig. 2c/d ) <CRPCAA (Fig. 2e/f )).
Meller et al. EJNMMI Research  (2015) 5:66 Page 4 of 11
With the radiolabelled peptide, the ascending order of
PSMA expression according to increasing androgen
deprivation tolerance could be affirmed. Androgen-
sensitive cells exhibited lower uptake than the
castration-resistant cells. The highest uptake was deter-
mined for abiraterone-tolerant cells. The observed differ-
ences between PSMA uptakes were significant for all the
different experimental groups after 3 h (p < 0.05). The
half-life-corrected uptake of untreated cell lines in-
creased significantly over time (p < 0.05). The uptake of
the labelled compound in the three subtypes was on a
relatively low level after 1 h but doubled after 3 h of in-
cubation (Fig. 3).
Internalisation experiments revealed a further increase
of total cell bound activity after 5 h compared to activity
after 3 h. Percentage of internalised peptide was about
30 % of membrane-bound activity in the investigated
three subtypes (Fig. 4).
Variation in androgen deprivation
Compared to control CRPC cells, treatment with
5 μmol/L abiraterone acetate (AA) over 48 h resulted in
a significant increased uptake of 68Ga-PSMA-HBED-CC
(p < 0.001) and decreased proliferation about 40 %. The
uptake after 3 h increased more than fivefold (Fig. 5a).
In androgen-sensitive revCRPC cells, androgen
deprivation treatment with 5 μmol/L AA resulted in an
eightfold higher uptake after 3 h. Further withdrawal of
testosterone from the medium (+AA −T) increased the
uptake up to tenfold (p < 0.001, Fig. 5b). In internalisa-
tion experiments, differences induced by ADT were
evident. In revCRPC, ADT induced an increase of mem-
brane bound and internalised 68Ga-PSMA-HBED-CC
(Fig. 4) whereby proliferation was significantly inhibited.
The growth was <50 % in ADT-treated revCRPC com-
pared to the revCRPC in the same assay. The activities
in the different fractions of ADT-treated revCRPC cells
were comparable to observed levels in CRPC and
CRPCAA.
The influence of AA treatments on PSMA expression
was confirmed by PSMA mRNA quantitation in CRPC
cells. On the mRNA level, PSMA expression increased
by more than 300 % within 4 weeks treatment with AA
(Fig. 6a). In androgen-sensitive revCRPC cells, the AA
Fig. 1 Western blot total protein extraction of the three cell lines
subtypes with different levels of androgen deprivation sensitivity
(revCRPC, CRPC, CRPCAA). Displayed is total PSMA protein at 100 kDa
and the housekeeping gene α-tubulin (a). Relative density was
determined by a chemiluminescent substrate (b)
Fig. 2 Immunohistological staining of PSMA in the three investigated cell lines subtypes. Cytoplasmic PSMA (brown signal) in revCRPC (a ×20, b
×60), CRPC (c ×20, d ×60) and CRPCAA (e ×20, f ×60)
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treatment combined with androgen withdrawal resulted
in an almost tenfold higher PSMA expression. RPL
housekeeping gene expression was not altered under
these treatments in both cell lines while androgen recep-
tor splice variant 7 (AR-V7) also increased markedly in
CRPC cells by AA treatment, whereas in androgen-
sensitive revCRPC cells androgen deprivation was best
indicated by PSMA expression (Fig. 6b).
Prolonged AA treatments of CRPC cells up to
7 months yielded another CRPC cell variant no longer
susceptible to continuous AA treatment. This cell vari-
ant was termed CRPCAA. In contrast to revCRPC and
CRPC whose androgen deprivation caused an increase
of 68Ga-PSMA-HBED-CC-uptake (Fig. 5), CRPCAA
revealed an elevated uptake of the peptide upon cessa-
tion of androgen deprivation and androgen supplemen-
tation (Fig. 7). In this cell line, peptide uptake was
significantly increased up to fivefold (p < 0.01) after 3 h
of application, when AA had been withdrawn from cell
culture media (−AA). Proliferation decreased in this cell
line by about 25 % after AA withdrawal. This level of up-
take remained constant when 1 nmol/L testosterone had
been added to AA withdrawal medium (−AA + T).
Discussion
PSMA is a novel and promising target for diagnostics
and therapy of metastatic prostate cancer, especially
when the androgen receptor is the persistent therapeutic
Fig. 3 Time-dependent uptake of 68Ga-PSMA-HBED-CC in androgen-sensitive (revCRPC), castration-resistant prostate cancer cells (CRPC) and
abiraterone-insensitive cells (CRPCAA). Displayed is the percentage uptake of applied radioactivity per 10
6 cells (mean ± SD; n = 9 cultures)
Fig. 4 Membrane binding and internalisation of 68Ga-PSMA-HBED-CC after 5 h of incubation in androgen-sensitive (revCRPC), castration-resistant
prostate cancer cells (CRPC) and abiraterone-insensitive cells (CRPCAA) as well as in revCRPC after 48 h ADT with testosterone (T) withdrawal and
5 μM abiraterone acetate (AA). Values are expressed as percentage of applied radioactivity bound to 106 cells. Mean ± SD (n = 3 cultures)
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target and pending cross resistances might occur in
subsequent androgen-directed therapies [30]. Several
groups focused on the relations between PSMA expres-
sion and other membrane antigens. Evans et al. found an
androgen receptor (AR) dependency of PSMA expres-
sion. AR-negative PCa cell lines consequently lack
PSMA expression [5]. They demonstrated a downregula-
tion of PSMA mRNA expression in AR-positive cell
lines after incubation with 10 nmol/L testosterone for
72 h. In our in vitro model, the basal 1 h uptake of
PSMA-binding peptide differed between castration-
resistant cells and the androgen-sensitive cell line. This
is consistent with the notion of our cell model represent-
ing androgen signalling in revCRPC with low androgen
receptor expression in the present of androgens
(1 nmol/L testosterone) and CRPC with overexpressed
androgen receptor in the absence of androgens [24, 31].
Our cell culture system represents different stages of
castration resistance (including the androgen-sensitive
and the AA-tolerant subtype) without the bias of
Fig. 5 Time-dependent binding of 68Ga-PSMA-HBED-CC in (a) castration-resistant prostate cancer (CRPC) cells with and without coincubation with
abiraterone acetate (AA, 5 μmol/L) and testosterone (T, 1 nmol/L) and (b) in androgen-sensitive revCRPC cells with and without AA-treatment
(5 μmol/L) or additional withdrawal of testosterone (−T) from the medium. Displayed is the percentage uptake of applied radioactivity per 106
cells (mean ± SD; n = 9 cultures)
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common mutations in androgen receptor of most other
PCa cell cultures.
Additionally, we were able to substantiate increasing
PSMA expression by increasing androgen deprivation
on the protein level. Differences between uptake mea-
surements and Western blot visualisation by chemilu-
minescent staining could readily be explained by the
differences in methods and substrates. While peptide
uptake represents the sum of membrane-bound and
internalised activity at varying kinetic speeds of both
processes in growing cell cultures, Western blot and
immunohistochemistry was performed with isolated
proteins or fixed cells using PSMA antibodies.
Eder et al. described the internalisation of 68Ga-
PSMA-HBED-CC [23, 32]. We could confirm these re-
sults and the ratio between the membrane-bound and
internalised fraction of the tracer. In addition, we found
an increasing uptake over time. Compared to the 1-h
value, the half-life-corrected value 3 h after peptide ad-
ministration was almost doubled. These findings were
observed in all three cell line subtypes. This might be an
important finding for in vivo applications, as we recently
could demonstrate a higher 68Ga-PSMA-HBED-CC up-
take 3 h after injection in metastatic and primary PCa,
too [33]. An increase over time seems to be a criterion
for differentiation between benign and malignant lesions.
This might be meaningful for differentiation of very
small lesions near by the detection limits in PET/CT and
also for PSMA-directed therapy. During the last decades,
several new potent therapeutic options for prostate
carcinoma have been developed. This resulted in a
decrease of prostate-carcinoma-related death despite an
Fig. 6 Time-dependent changes of PSMA mRNA expression,
androgen receptor splice variant 7 (AR-V7) and ribosomal protein
L13a (RPL) housekeeping gene in (a) CRPC cells under abiraterone
acetate (AA) treatment and (b) revCRPC cells under AA treatment
and additional androgen withdrawal from the medium
Fig. 7 Time-dependent changes of 68Ga-PSMA-HBED-CC uptake 1 and 3 h after application in abiraterone-tolerant cells 48 h (CRPCAA) after
abiraterone acetate (AA) withdrawal with or without additional application of 1 nmol/L testosterone (T). Displayed is the percentage uptake of
applied radioactivity per 106 cells (mean ± SD; n = 9 cultures)
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increasing incidence of the disease [2, 4]. The develop-
ment of different castration regimen and the pharma-
ceutical blockade of the androgen receptor has been
optimised and reached clinical application. Enzalutamide
(Xtandi®) is a second-generation antiandrogen compet-
ing with ligand binding to the androgen receptor, and
abiraterone acetate (Zytiga®) is an inhibitor of intratu-
moral steroidogenesis. In contrast, LHRH agonists in-
hibit androgen synthesis only in the testes but not in the
adrenal and prostate cancer cells.
The first data of an increasing PSMA expression and
androgen receptor activation by abiraterone acetate and
enzalutamide were presented in a preclinical study by
flow cytometry in CRPC [21]. Our data confirm this in-
crease monitored on the mRNA level substantiating
these results on the protein level. Furthermore, we dem-
onstrated an increasing uptake of PSMA-binding tracer
immediately after intensified androgen deprivation not
only in CRPC but also in androgen-sensitive cell lines.
In our internalisation experiments, the tracer binding
properties of 48-h ADT-treated androgen-sensitive cells
were comparable to those of ADT-tolerant cells, albeit
tracer binding was concomitant with proliferation de-
crease. The intracellular blocking of androgen synthesis
seems to increase not only the expression of the andro-
gen receptor but also of PSMA. This was confirmed by
our uptake measurements for the early phase and for
long-term application over several weeks. Further inves-
tigations demonstrated the cross-talk between androgen
receptor and phosphoinositide 3-kinase (PI3K) signalling
pathway and enhanced AR signalling after inhibition of
PI3K pathway [21]. Another investigation observed the
regulation of PI3K pathway by PSMA knockdown [34].
Therefore, it can be hypothesised that the PI3K pathway
is a link between PSMA and AR. Notwithstanding
mechanistic details, the main prospect of this study is
the positioning of PSMA as a potential therapeutic tar-
get clearly marked in PET under pending therapy failure
when alternative subsequent therapy is inappropriate
due to cross resistances.
In our experiments with AA-insensitive CRPCAA
cells, an increased peptide uptake could also be in-
duced by AA withdrawal for 48 h. AA withdrawal
inhibited proliferation in these cells considerably. This
is in coincidence with clinical findings in the litera-
ture. Recently, a case of biochemical and metabolic
response to AA withdrawal with decreasing tumour
size and choline uptake after AA rechallenge for
3 months has been documented by 18F-choline PET/
CT [35]. This could be explained by a decreased need
of membrane biosynthesis in a shrinking tumour. In
contrast, other groups reported that PSMA and the
prostate-specific antigen (PSA) are inversely correlated
under androgen deprivation [5, 36].
It is well known that ADT decreased PCa growth in
androgen-sensitive tumours [3, 37]. In a castration-
resistant situation, ADT cessation seems to decrease
tumour proliferation, too [35]. Therefore, increasing
PSMA expression might be a sign for tumour response
after variation in androgen deprivation in general. Our
preliminary study holds an explanation for this
phenomenon in the overexpression of CYP17A1 and an-
drogen receptor in CRPCAA cells and normalised ex-
pression after AA withdrawal and supplementation with
low concentrations of testosterone [38]. The underlying
molecular mechanisms of these early effects have to be
elucidated in further investigations.
Conclusions
The investigated three PCa cell culture subtypes repre-
sent a serial preclinical model of androgen deprivation
therapy as a proxy for clinical situations with differing
basal PSMA expression. The uptake of PSMA-binding
tracers could be stimulated by therapeutic effective
short-term variation in premedication in all stages of
ADT response. These complex interactions have to be
considered in the interpretation of diagnostic imaging
using PSMA ligands as well as in the optimal timing of
PSMA-based therapies.
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